GH Research Plc (GHRS)
14.72
+0.66
(+4.69%)
USD |
NASDAQ |
Apr 01, 16:00
14.82
+0.10
(+0.68%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 962.43M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 36.80% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 3.441 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0018 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland. |
| URL | http://www.ghres.com |
| Investor Relations URL | https://investor.ghres.com/ |
| HQ State/Province | Dublin |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 07, 2026 (est.) |
| Last Earnings Release | Mar. 05, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland. |
| URL | http://www.ghres.com |
| Investor Relations URL | https://investor.ghres.com/ |
| HQ State/Province | Dublin |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 07, 2026 (est.) |
| Last Earnings Release | Mar. 05, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |